Analysis of the Circulating Metabolome of Patients with Cutaneous, Mucosal and Uveal Melanoma Reveals Distinct Metabolic Profiles with Implications for Response to Immunotherapy
Authors:
- Maysa VilbertMVMaysa Vilbert
- Erica C. KochEKErica C. Koch
- April A. N. RoseARApril A. N. Rose
- Rob C. LaisterRLRob C. Laister
- Diana GrayDGDiana Gray
- Valentin SotovVSValentin Sotov
- Susanne PennySPSusanne Penny
- Anna SpreaficoASAnna Spreafico
- Devanand M. PintoDPDevanand M. Pinto
- Marcus O. ButlerMBMarcus O. Butler
- Samuel D. SaibilSSSamuel D. Saibil
Open Access
Abstract
Cutaneous melanoma (CM) patients respond better to immune checkpoint inhibitors (ICI) than mucosal and uveal melanoma patients (MM/UM). Aiming to explore these differences and understand the distinct response to ICI, we evaluated the serum metabolome of advanced CM, MM, and UM patients. Levels of 115 metabolites were analyzed in samples collected before ICI, using a targeted metabolomics platform. In our analysis, molecules involved in the tryptophan-kynurenine axis distinguished UM/MM from CM. UM/MM patients had higher levels of 3-hydroxykynurenine (3-HKyn), whilst patients with CM were found to have higher levels of kynurenic acid (KA). The KA/3-HKyn ratio was significantly higher in CM versus the other subtypes. UM, the most ICI-resistant subtype, was also associated with higher levels of sphingomyelin-d18:1/22:1 and the polyamine spermine (SPM). Overall survival was prolonged in a cohort of CM patients with lower SPM levels, suggesting there are also conserved metabolic factors promoting ICI resistance across melanoma subtypes. Our study revealed a distinct metabolomic profile between the most resistant melanoma subtypes, UM and MM, compared to CM. Alterations within the kynurenine pathway, polyamine metabolism, and sphingolipid metabolic pathway may contribute to the poor response to ICI. Understanding the different metabolomic profiles introduces opportunities for novel therapies with potential synergic activity to ICI, to improve responses of UM/MM.Keywords
All Related Versions
This publication has 40 references indexed in Scilit:
- The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and careExpert Review of Anticancer Therapy, 2018
- Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and BeyondAnnals of Surgical Oncology, 2018
- Sphingolipid metabolism in cancer signalling and therapyNature Reviews Cancer, 2017
- Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manualCA: A Cancer Journal for Clinicians, 2017
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced MelanomaNew England Journal of Medicine, 2017
- The Skyline ecosystem: Informatics for quantitative mass spectrometry proteomicsMass Spectrometry Reviews, 2017
- Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled AnalysisJournal of Clinical Oncology, 2017
- The efficacy of anti‐PD‐1 agents in acral and mucosal melanomaCancer, 2016
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaNew England Journal of Medicine, 2015
- Ido expression by dendritic cells: tolerance and tryptophan catabolismNature Reviews Immunology, 2004